Obeticholic Acid for Prevention in Barrett's Esophagus (NCT04939051)
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial studies the effect of obeticholic acid in treating patients with Barrett's esophagus. Bile acids present in duodenogastroesophageal reflux contribute to neoplastic progression in Barrett's esophagus. Obeticholic acid has shown anti-cholestatic, anti-inflammatory and anti-fibrotic effects mediated by FXR activation. It down regulates bile acid availability and decreases proinflammatory cytokine production including IL-1beta and TNFalpha in human enterocytes and immune cells. This chain of events reduces the bile acid exposure in esophagus tissue thereby limiting bile acid induced damage and dysplastic progression.
Who can join: Review the eligibility criteria below.
Location: University of Kansas Cancer Center — Kansas City, Kansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- University of Kansas Cancer Center — Kansas City, Kansas
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- Washington University School of Medicine — St Louis, Missouri
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Case Western Reserve University — Cleveland, Ohio
- Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
📞 Contact the Study Coordinator
Phone: (816) 861-4700
Email: abansal@kumc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Barrett Esophagus
- Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus — Baltimore, Maryland
- Coordinating Center: Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy — Jacksonville, Florida
- Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE) — Birmingham, Alabama
- Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy — Boston, Massachusetts
- Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System — Orange, California
- Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation — Los Angeles, California
Explore by condition: All Barrett Esophagus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.